Danal's Nursing Tender: How Much Profit Really Depends on the New Tariff Structure

The main article already argued that the nursing tender is the central swing factor for Danal in 2026. This follow-up isolates a narrower question: how much of Danal's profit really depends not just on the tariff level, but on the tariff design and on the quality criteria that will determine who can actually earn acceptable returns under the new tender.

This is not just another broad regulatory question. Nursing is the group's biggest engine, but it is not an engine with excess margin. In 2025 the segment generated NIS 1.552 billion of revenue and NIS 99.5 million of operating profit. That is only a 6.4% operating margin. At the same time, revenue from the National Insurance Institute alone accounted for 48.8% of group revenue. So even a change that looks incremental on paper, in the tariff, in the tariff structure, or in the way quality is scored, can translate into a much larger change in profit.

That is the core point. Danal is not entering the tender from an operationally weak position. Quite the opposite. It comes in with 42 branches, 673 staff employees in nursing, a national service center, control systems, and a service model the company itself describes as maintaining internal quality standards above what the purchaser necessarily requires. Precisely because of that, the economics of the new tender will decide whether this scale is a rewarded advantage, or a fixed cost layer that turns into margin pressure.

A Huge Segment, But Not a Fat Margin Cushion

At first glance, the 2025 numbers look comfortable. Nursing-segment revenue rose to NIS 1.552 billion from NIS 1.474 billion, and operating profit rose to NIS 99.5 million from NIS 94.5 million. But revenue growth and profit growth were almost identical, roughly 5.3% in both lines. In other words, the segment grew, but it did not widen its margin.

That point matters enormously for the tender read. If margin had expanded sharply, one could argue there is enough cushion to absorb a less favorable tender. That is not the picture here. Danal is entering the tender from a segment that works well, but works on relatively tight economics. A 6.4% operating margin in a business built on wages, travel, pensions, branches, control processes and quality requirements is not the kind of margin that leaves room for meaningful tariff error.

Even the exit rate in Q4 does not change the basic conclusion. On the one hand, the last quarter of 2025 was better than the comparable quarter: revenue rose to NIS 397.6 million from NIS 375.6 million, and operating profit rose to NIS 23.4 million from NIS 17.8 million. On the other hand, even after that improvement, the segment was still operating at a single-digit margin. So there was improvement, but not proof that the business is sitting on economics wide enough to absorb a weaker tender design comfortably.

This leads to the first conclusion: the new tender does not threaten only some distant future profitability. It touches the engine that is already operating today on stable but fairly tight economics.

Where The Tender Economics Actually Sit

To understand the risk, it helps to start with what the company says explicitly. Note 20 says the new tender includes material changes in the tariff and even in the tariff structure, and that if the tender terms are not corrected they could materially hurt nursing-segment profitability and, as a result, group profitability. The company also says it cannot yet estimate the size of that impact. That is a strong warning, not a side note.

But the economics here are broader than the simple question of whether the hourly tariff goes up or down. The new tender does not include price competition. It is a list tender, where winners are determined by threshold conditions and quality criteria. That shifts the real question to something more specific: do the new scoring system and the new tariff design actually pay for the service model in practice.

Danal describes a service model that does not look like a light brokerage business. Social workers, nurses and inspectors perform home visits and also visit during hospitalization. The company says this reflects internal high standards for quality and continuity of care, not necessarily the full set of requirements imposed by the service purchaser. On top of that, the presentation emphasizes a national service center, CRM and control tools, and a nationwide network of 42 branches.

That is Danal's advantage in the tender, but it is also the center of its sensitivity. If the new quality framework assigns real value to quality, experience, geographic reach and professional control, Danal's platform could work in its favor. If the new tariff structure does not compensate that layer adequately, or if the new criteria require additional cost without equivalent reimbursement, that same platform becomes a source of margin pressure.

The company also says it is already trying to reduce the potential damage, including by adapting its operations to the current tender conditions. That matters, but it also highlights what is still missing from the disclosure: there is still no number showing how much cost can realistically be taken out of the system without hurting service quality, branch coverage, or the quality score itself.

So a reading that focuses only on the phrase "no price competition" misses half the story. There is no discount war here, but there absolutely is a fight over the economics of the model.

The Tender Is Hitting a Market That Is Already Moving in a Less Helpful Direction

Another easy mistake is to assume the tender alone will determine the economics of nursing. In practice, the tender is landing in a market that was already shifting in a less comfortable direction for operators.

First, the company says that based on its experience the share of beneficiaries choosing to receive the benefit in cash rose meaningfully and reached about 19.85% in 2025. This is not just an abstract policy point. It means that a larger part of the eligible market can move out of the actual service channel. Even without a sudden tender shock, part of the market is already moving from service hours toward cash.

Second, Danal itself grew by about 3.0% in the real nursing market in 2025, while the market grew by about 3.3%. This is not a sign of collapse. But it does mean the company is not entering the tender while opening a clear lead over the market. It is entering mainly from a position of preserving scale, not accelerating share gains.

Third, management estimates its share of the nursing market delivered through caregivers, excluding full cash benefits, stood at about 12.9% in December 2025. That is a high share and clearly points to operational scale and leadership. But it also sharpens the sensitivity: when you are large, a change in conditions hits larger absolute numbers.

And fourth, the local professional committees do not only decide eligibility and hours. They are also allowed to shift a beneficiary from one provider to another, mainly for professional reasons. So the new tender will not only determine whether Danal is "in" or "out." It will also shape the terms on which the company competes for share inside a market where operational quality and the relationship with the patient still matter after the tender itself.

The Timeline Suggests 2026 Is a Bridge Year

This is where the most important 2026 reading comes in. On October 28, 2025, the National Insurance Institute extended the current engagement with service providers, including Danal, through December 31, 2026, plus a one-year option, or until the tender process is completed and contracts are signed with the winners, whichever comes first. At the same time, the appeal hearing was set for April 19, 2026, and after the additional clarifications file, the last date for submitting bids was set for April 29, 2026.

That makes 2026 look, at least for now, like a bridge year, not a year of certainty. On the one hand, a meaningful part of activity may still continue under the existing framework. On the other hand, the market will not wait for the financial statements to show the full effect. It will try to decide already around April 2026 whether the final tender framework really fixed the friction points the company and the industry association had been fighting over, or whether the problem was mainly delayed.

That also creates a gap between accounting and market reading. In the 2025 report one can still see a nursing segment that is relatively stable, with higher revenue, higher profit and unchanged margin. But if the tender settles on weak economics, the 2025 report will look retrospectively less reassuring, because it will read more like a peak of the old economics than a clean base for the new ones.

That is exactly why the company's warning that it cannot yet estimate the impact matters so much. This is not just technical uncertainty. It is an admission that the critical variable has not yet been settled, and that 2027 profitability cannot be drawn in a straight line from 2025 numbers.

Conclusion

Current thesis in one line: Danal's nursing profit depends less on whether the company remains a leading player and more on whether the new tariff structure and quality rules actually pay for the large, quality-heavy service model it already runs.

What is working today is clear. Danal has a large nursing platform, broad coverage, a professional control layer, meaningful market share and a leading position in a fragmented market. What is still missing for a cleaner thesis is confidence that the new tender will not compress economics exactly where the segment is most sensitive, the profitability of each service hour.

That is why the most important question for readers is not whether Danal will "win" the tender. A player of this scale is likely to remain part of the system. The sharper question is different: will it remain part of the system on the same economics.

If April 2026 shows that the final tender formula really fixes the tariff and quality gaps, 2025 can still be read as a stable base for a bridge year. If not, 2025 may turn out, in hindsight, to have been the year when profit still looked solid while the real risk was already sitting at the door.